Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2024 09:35 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24,...
September 18, 2024 16:05 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
August 13, 2024 16:05 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in...
May 29, 2024 16:05 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of...
May 14, 2024 16:05 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong...
April 11, 2024 07:55 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial...
April 09, 2024 16:05 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
March 28, 2024 16:05 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
March 19, 2024 08:30 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026...
March 14, 2024 16:05 ET | Source: Enliven Therapeutics, Inc.

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in...